Purchase this article with an account.
Susanna S Park; Bone marrow stem cell therapy for retinal disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2200. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Presentation Description :
Bone marrow contains various multi-potent stem cells that play an important role in normal tissue repair and maintenance. By harvesting these stem cells from bone marrow and injecting these cells directly into the eye, the regenerative potential of these stem cells may be optimized. Hematopoietic stem cells and mesenchymal stem cells are two bone marrow stem cells that have been studied. The regenerative effects of these cells appear to be via paracrine trophic effects on target tissue. Direct tissue integration has also been observed. Mesenchymal stem cells can be easily harvested and expanded using tissue culture. However, safety concerns have been raised regarding intravitreal injection of these cells in preclinical models. CD34 is a commonly used cell surface marker for human hematopoietic stem cells and endothelial progenitor cells. Intravitreal injection of human CD34+ cells from bone marrow was well tolerated in preclinical models of retinal degeneration and ischemia. Long-term retinal vascular integration of these human cells has been demonstrated in preclinical model of retinal ischemia. Early phase clinical trial has been conducted using intravitreal injection of autologous CD34+ cells from bone marrow to treat vision loss associated with retinal ischemia or degeneration. The study showed safety and feasibility of this cell therapy. A phase I/II prospective randomized sham controlled study is planned to further explore this cell therapy to treat vision loss associated with retinal vein occlusion (TRUST Study). This presentation is an overview of preclinical and early phase clinical studies that have been conducted using bone marrow stem cells to treat retinal ischemia and degeneration.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.
This PDF is available to Subscribers Only